RxDoctor Payments DataLook up a doctor →

Elias Hsu, MD

Urology · Denver, CONPI 1902077332

Payments from drug & device makers

$23,294in general payments, 2019–2025

Across 386 payments — averaging $60.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$12K
  • Medtronic$2K
  • AbbVie$1K
  • Boston Scientific$1K
  • Johnson & Johnson$632
  • Coloplast$581
  • plus $6K from 47 others

What the payments were for

  • Consulting fees$1,0555%
  • Speaking & faculty fees$11,04547%
  • Travel & lodging$1000%
  • Food & beverage$10,99547%
  • Education$1000%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,294 in reported general payments places this provider in the 85th percentile of 225 urology providers in Colorado.

See all urology providers in Colorado

Medicare billing

Part B allowed, 2024
$127,506
Medicare patients
394
Services billed
2,875

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron166$170,841
ThiolaTiopronin12$91,001
GemtesaVibegron35$33,417
Methenamine Hippurate159$13,032
Fesoterodine Fumarate ErFesoterodine Fumarate27$3,830
Trospium Chloride28$2,938
Trospium Chloride ErTrospium Chloride12$2,404
Estradiol30$1,978
Tamsulosin Hcl157$1,944
Solifenacin Succinate20$1,357
Desmopressin Acetate13$581
Finasteride36$458
Alfuzosin Hcl ErAlfuzosin Hcl14$415
Gabapentin18$392
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst21$385

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$12,127$170,841166 claims
Sumitomo Pharma America, Inc.Gemtesa$445$33,41735 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 225 urology providers in Colorado.

Other urology in Denver

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →